Figure 5.
Pevonedistat reduces disease burden and prolongs survival in the MPL W515L mouse model of myelofibrosis. (A-C) Cellular measurements of MPL W515L transplanted mice (n = 8 for each group) after treatment with pevonedistat (60 mg/kg), ruxolitinib (90 mg/kg), or combination. White blood cells (A); hematocrit (B); and platelets (C). **P < .01; ***P < .001; ****P < .0001 by 2-way ANOVA with Dunnett’s multiple comparisons test. (D) Normalized spleen weights of mice at endpoint. **P < .01; ***P < .001 by 1-way ANOVA with Dunnett’s multiple comparisons test. (E) Kaplan-Meier survival curve of MPL W515L mice with log-rank P statistics. (F) Representative H&E and reticulin immunohistochemistry staining of BM from mouse tibias at endpoint. Scale bar: 40 µm.

Pevonedistat reduces disease burden and prolongs survival in the MPL W515L mouse model of myelofibrosis. (A-C) Cellular measurements of MPL W515L transplanted mice (n = 8 for each group) after treatment with pevonedistat (60 mg/kg), ruxolitinib (90 mg/kg), or combination. White blood cells (A); hematocrit (B); and platelets (C). **P < .01; ***P < .001; ****P < .0001 by 2-way ANOVA with Dunnett’s multiple comparisons test. (D) Normalized spleen weights of mice at endpoint. **P < .01; ***P < .001 by 1-way ANOVA with Dunnett’s multiple comparisons test. (E) Kaplan-Meier survival curve of MPL W515L mice with log-rank P statistics. (F) Representative H&E and reticulin immunohistochemistry staining of BM from mouse tibias at endpoint. Scale bar: 40 µm.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal